{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:42:19Z","timestamp":1780490539662,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HEROES FOUNDATION"},{"name":"Lions Control Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) affects\u2009&gt;\u200978% of oncology patients and causes detrimental side effects. There may be practice heterogenicity in CIPN management amongst oncologists treating pediatric, adolescent young adult (AYA), and adult patients with cancer. We sought to evaluate the practice patterns of oncologists regarding their management of CIPN in AYAs with cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A survey was developed and sent to pediatric and medical oncologists from across the United States. Scenarios included an 18-year-old receiving vincristine (VCR) with mild neuropathy (Scenario 1) and moderate\/severe neuropathy (Scenario 2). Respondents were asked how they would manage each patient. Differences between pediatric and medical oncologists\u2019 management were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 179 responses were submitted by 132 (73.7%) pediatric, 44 (24.6%) medical oncologists, and 3 (1.6%) oncologists who care for both pediatric and adult patients. Over half of respondents for Scenario 1 would refer the patient to physical therapy (PT) (56.8%), 38.1% would prescribe a pharmacologic agent, and 27.8% would dose reduce\/omit vincristine. For Scenario 2, most (81.8%) would dose reduce\/omit vincristine, 69.3% would refer for PT, and 44.9% would start a pharmacologic agent. On multivariable analyses, medical oncologists were more likely to dose reduce\/omit vincristine for Scenario 1 (OR, 7.68; 95% CI, 3.24\u201318.22) and Scenario 2 (OR, 5.52; 95% CI, 1.37\u201322.18, and less likely to refer to PT for Scenario 1 (OR, 0.12; 95% CI, 0.05\u20130.31) and Scenario 2 (OR, 0.18; 95% CI, 0.08\u20130.41).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our survey suggests a broad spectrum of CIPN management in AYAs with cancer. The heterogenicity in practices and significant differences between pediatric and medical oncologists underscores an urgent need to better understand the source of heterogeneity in CIPN management practices and barriers to evidence-based care delivery.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09387-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:12:55Z","timestamp":1743887575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Practice patterns in the diagnosis and management of chemotherapy-induced peripheral neuropathy in adolescents and young adults with cancer: a survey of oncologists"],"prefix":"10.1007","volume":"33","author":[{"given":"Jennifer A.","family":"Belsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Lee","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Leisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etan","family":"Orgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"16","key":"9387_CR1","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.28748","volume":"120","author":"MA Smith","year":"2014","unstructured":"Smith MA et al (2014) Declining childhood and adolescent cancer mortality. Cancer 120(16):2497\u20132506","journal-title":"Cancer"},{"issue":"14","key":"9387_CR2","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1200\/JCO.2009.22.3339","volume":"27","author":"LL Robison","year":"2009","unstructured":"Robison LL et al (2009) The childhood cancer survivor study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27(14):2308\u20132318","journal-title":"J Clin Oncol"},{"issue":"10","key":"9387_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S2352-4642(18)30236-0","volume":"2","author":"KL Bjornard","year":"2018","unstructured":"Bjornard KL et al (2018) Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health 2(10):744\u2013754","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"9387_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40122-017-0092-3","volume":"7","author":"V Brozou","year":"2018","unstructured":"Brozou V, Vadalouca A, Zis P (2018) Pain in platin-induced neuropathies: a systematic review and meta-analysis. Pain Ther 7(1):105\u2013119","journal-title":"Pain Ther"},{"issue":"2","key":"9387_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","volume":"27","author":"AB O\u2019Connor","year":"2009","unstructured":"O\u2019Connor AB (2009) Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 27(2):95\u2013112","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"9387_CR6","doi-asserted-by":"publisher","first-page":"e29550","DOI":"10.1002\/pbc.29550","volume":"69","author":"RL Rodwin","year":"2022","unstructured":"Rodwin RL et al (2022) Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatr Blood Cancer 69(3):e29550","journal-title":"Pediatr Blood Cancer"},{"issue":"28","key":"9387_CR7","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325\u20133348","journal-title":"J Clin Oncol"},{"issue":"10","key":"9387_CR8","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31(10):1306\u20131319","journal-title":"Ann Oncol"},{"key":"9387_CR9","unstructured":"In Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. 2013: London"},{"issue":"8","key":"9387_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","volume":"17","author":"RA Swarm","year":"2019","unstructured":"Swarm RA et al (2019) Adult cancer pain version 3.2019 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(8):977\u20131007","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"9387_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jamaoncol.2022.6132","volume":"9","author":"I Turgeman","year":"2023","unstructured":"Turgeman I, West H (2023) Adolescents and young adults with cancer. JAMA Oncol 9(3):440\u2013440","journal-title":"JAMA Oncol"},{"issue":"2","key":"9387_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA et al (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"issue":"1","key":"9387_CR13","first-page":"18","volume":"70","author":"AJ Beijers","year":"2012","unstructured":"Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70(1):18\u201325","journal-title":"Neth J Med"},{"issue":"7","key":"9387_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","volume":"51","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Jakubowiak AJ (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 51(7):1178\u20131187","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"9387_CR15","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","volume":"88","author":"AA Argyriou","year":"2014","unstructured":"Argyriou AA et al (2014) Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol 88(9):1669\u20131679","journal-title":"Arch Toxicol"},{"issue":"1","key":"9387_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.nrl.2016.05.008","volume":"33","author":"S Exp\u00f3sito Vizca\u00edno","year":"2018","unstructured":"Exp\u00f3sito Vizca\u00edno S et al (2018) Neuropathic pain in cancer patients treated with bortezomib. Neurologia (Engl Ed) 33(1):28\u201334","journal-title":"Neurologia (Engl Ed)"},{"issue":"11","key":"9387_CR17","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1007\/s00520-016-3329-5","volume":"24","author":"NR Zanville","year":"2016","unstructured":"Zanville NR et al (2016) Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support care cancer 24(11):4779\u20134789","journal-title":"Support care cancer"},{"issue":"5","key":"9387_CR18","doi-asserted-by":"publisher","first-page":"151685","DOI":"10.1016\/j.soncn.2024.151685","volume":"40","author":"G Kanzawa-Lee","year":"2024","unstructured":"Kanzawa-Lee G, Krauss JC, Knoerl R (2024) Exploring chemotherapy-induced peripheral neuropathy management practice patterns among oncology clinicians. Semin Oncol Nurs 40(5):151685","journal-title":"Semin Oncol Nurs"},{"issue":"2","key":"9387_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/NCC.0000000000001082","volume":"46","author":"R Knoerl","year":"2023","unstructured":"Knoerl R et al (2023) Exploring clinicians\u2019 perspectives of barriers to chemotherapy-induced peripheral neuropathy assessment and management in oncology practice: a qualitative analysis of semi-structured interviews. Cancer Nurs 46(2):103\u2013110","journal-title":"Cancer Nurs"},{"issue":"Supplement 1","key":"9387_CR20","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1182\/blood-2022-167046","volume":"140","author":"SK Parsons","year":"2022","unstructured":"Parsons SK et al (2022) Peripheral neuropathy in children with high risk Hodgkin lymphoma (HL): the role of protocol-stipulated dose modification in the children\u2019s oncology group (COG) AHOD1331 study. Blood 140(Supplement 1):6550\u20136551","journal-title":"Blood"},{"issue":"17_supp","key":"9387_CR21","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","volume":"41","author":"AF Herrera","year":"2023","unstructured":"Herrera AF et al (2023) SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol 41(17_supp):LBA4\u2013LBA4","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09387-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:10:52Z","timestamp":1745305852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09387-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["9387"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09387-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted IRB approval through Indiana University and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"350"}}